Evidence map›Paper›PMID 42811231›Full record

ReviewAAPS PharmSciTech2026

Navigating Surfactant Selection in In Vitro Dissolution Testing: Mechanistic Insights and Practical Strategies.

Sushesh Srivatsa Palakurthi, Niloufar Salehi, Jie Shen, Sanjaykumar Patel, Nikoletta Fotaki, Deanna Mudie, Sumedha Kapre, Pradnya Bapat, Christopher Rego, David B Turner and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sushesh Srivatsa Palakurthi *Department of Pharmaceutical Sciences, Texas A&M Irma Lerma Rangel College of Pharmacy, Kingsville, Texas, 78363, USA.ORCID http://orcid.org/0009-0001-4337-1632
Niloufar Salehi *Eli Lilly & Company, Indianapolis, Indiana, 46285, USA.ORCID http://orcid.org/0000-0002-0651-4251
Jie ShenDepartment of Pharmaceutical and Biomedical Sciences, Northeastern University, Boston, Massachusetts, 02115, USA. jie.shen@northeastern.edu.ORCID http://orcid.org/0000-0002-9504-8650
Sanjaykumar PatelMerck & Co., Inc.,, Rahway, New Jersey, 07065, USA. sanjaykumar.patel@merck.com.ORCID http://orcid.org/0009-0006-2225-1005
Nikoletta FotakiDepartment of Life Sciences, University of Bath, Bath, BA2 7AY, UK.ORCID http://orcid.org/0000-0003-1826-7363
Deanna MudieSimulations Plus, Research Triangle Park, Durham County, North Carolina, 27709, USA.ORCID http://orcid.org/0000-0002-3586-5069
Sumedha KapreDepartment of Pharmaceutical Sciences, Texas A&M Irma Lerma Rangel College of Pharmacy, Kingsville, Texas, 78363, USA.ORCID http://orcid.org/0009-0009-9736-1171
Pradnya BapatEli Lilly & Company, Indianapolis, Indiana, 46285, USA.ORCID http://orcid.org/0009-0006-4821-1327
Christopher RegoAnalytical Development Synthetic Molecules, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, 02142, USA.ORCID http://orcid.org/0009-0005-7913-0856
David B TurnerCertara, Simcyp Division, Sheffield, S1 2BJ, UK.ORCID http://orcid.org/0000-0001-6130-5914
Omid Arjmandi-TashPfizer, Sandwich, Kent, CT13 9NJ, UK.ORCID http://orcid.org/0000-0001-6199-9186
Zizhao XuDepartment of Pharmaceutical and Biomedical Sciences, Northeastern University, Boston, Massachusetts, 02115, USA.ORCID http://orcid.org/0009-0001-9225-0896
Shriram M PathakEisai Ltd., Hatfield, AL10 9SN, UK.ORCID http://orcid.org/0000-0002-3398-8890
Karina I VazquezEli Lilly & Company, Indianapolis, Indiana, 46285, USA.ORCID http://orcid.org/0009-0008-2012-930X
Vivian GrayV.A. Gray Consulting, Inc.,, Hockessin, Delaware, 19707, USA.ORCID http://orcid.org/0000-0003-1450-8780

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vitro dissolution testing is central to pharmaceutical development, yet it is increasingly challenged by poorly soluble drugs, which account for over 40% of marketed products and up to 90% of new chemical entities, for which dissolution often limits absorption. Surfactants are widely incorporated into dissolution media to achieve sink conditions and improve the discriminatory powder of dissolution methods, but inappropriate surfactant selection or concentration can alter drug release mechanisms, mask formulation differences, and reduce biopredictive performance. This review examines the mechanisms of surfactant action, including wetting enhancement, micellar solubilization, and drug-surfactant interactions, together with the physicochemical properties of anionic, cationic, non-ionic, and zwitterionic surfactant relevant to dissolution testing. Building on these principles, we discuss practical considerations for surfactant selection, concentration optimization, analytical compatibility, surfactant quality and source variability, formulation-specific considerations for enabled drug delivery systems, integration with physiologically based biopharmaceutics modeling, and evolving regulatory expectations. Together, these provide a practical framework for developing robust, reproducible, and discriminating dissolution methods that better reflect in vivo performance and support decision-making across drug development.

Indexed as

Surface-Active AgentsChemistry, PharmaceuticalDrug Delivery SystemsDrug DevelopmentDrug LiberationHumansMicellesPharmaceutical PreparationsSolubilityMicellesPharmaceutical PreparationsSurface-Active Agentsbiorelevantin vitro dissolution testingphysiologically based biopharmaceutics modeling (PBBM)poorly soluble drugsquality controlsink conditionssurfactant selection

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.